Navigation Links
Less Than Two-Thirds of Surveyed Pharmacy Directors Expect to Reimburse Both Onglyza and Alogliptin Once They are Available for the Treatment of Type 2 Diabetes
Date:2/2/2009

Contract Negotiation is Leading Factor in Improving Formulary Placement of Newer Entrants to Antidiabetic Market, According to a New Report from HealthLeaders-InterStudy and Fingertip Formulary

NASHVILLE, Tenn. and GLEN ROCK, N.J., Feb. 2 /PRNewswire/ -- HealthLeaders-InterStudy and Fingertip Formulary find that less than two-thirds of surveyed pharmacy directors expect to reimburse both Bristol-Myers Squibb/AstraZeneca's Onglyza and Takeda's alogliptin once they become available. Sixty-two percent of surveyed pharmacy directors say they expect their managed care organization to reimburse both products, while 26 percent say they expect their organization to reimburse only one. Seventy-eight percent of surveyed pharmacy directors say it is either likely or very likely they will reimburse Novo Nordisk's Victoza upon FDA approval.

According to the new Formulary Forum report entitled Formulary Advantages in Type 2 Diabetes: Impact of Current and Future DPP-IV Inhibitors and GLP-1 Analogues on Advantaged Reimbursement Status for Key Brands, 62 percent of surveyed pharmacy directors say their managed care organization would place Onglyza or alogliptin on Tier 1 or 2 if the agent were priced at $4.00 per treated day, but fewer (24 percent) would place it on Tier 1 or 2 if priced at $5.00 per treated day.

The report also finds that more surveyed pharmacy directors say that contract negotiations are important when improving the formulary position of Merck's Januvia and Amylin/Eli Lilly's Byetta than say safety or efficacy gains leading to downstream cost savings. Both recent entrants in the antidiabetic market, Januvia and Byetta are covered on 85 percent of health plans.

"Our survey reveals that contracting is a leading factor for pharmacy directors looking at products in the antidiabetic market," said Michael Malec
'/>"/>

SOURCE HealthLeaders-InterStudy; Fingertip Formulary
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. More than two-thirds of sexually active NYC youth use condoms, but other forms of birth control lag
2. Survey: Two-thirds of Illinois public schools provide comprehensive sex education
3. Erbitux Works Well for Two-Thirds of Colon Cancer Patients
4. UNC study: Two-thirds of severe sports injuries to female students due to cheerleading
5. Almost Two-Thirds of Americans Meet Exercise Guidelines
6. Despite Availability of Generic Equivalents, Two-Thirds of Neurologists Will Continue to Prescribe Branded Anti-Epileptic Drugs to Epilepsy Patients
7. World Vision Index of Concern: Half of Americans Surveyed Said They Would Be Willing to Pay More Taxes to Combat AIDS
8. Eighty-Nine Percent of Surveyed Rheumatologists Say They Will Prescribe Roche/Chugais Actemra for Rheumatoid Arthritis
9. Surveyed Neurologists in Both the U.S. and Europe Would Welcome an Antiepileptic Drug That is Administered Once-Daily
10. Half of Full-Time Employees Surveyed Dont Understand Health Insurance Coverage for Cancer-Related Medical Expenses
11. Surveyed Gastroenterologists Indicate That Humira Has Advantages Over Remicade in Maintaining Clinical Remission of Crohns Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2014)... Fairfax, Va., April 23, 2014 The American Society ... guideline, "The Role of Postoperative Radiation Therapy for ... the use of adjuvant radiation therapy in the ... is published in the May-June 2014 issue of ... clinical practice journal of ASTRO. The full-length guideline ...
(Date:4/23/2014)... University researchers have developed a way to detect and ... tiny gold particles with tails of synthetic DNA., A ... biological engineering, used gold nanoparticles to target and bind ... RNA splice variants, which can indicate the presence and ... splice variants in a cell can be determined by ...
(Date:4/23/2014)... A novel compound that targets an important brain ... cocaine addiction behaviors, including relapse behavior, a University at ... strong evidence that this may be a novel lead ... medications exist., The UB research was published as an ... , In the study, the compound, RO5263397, severely blunted ...
(Date:4/23/2014)... 23, 2014Men whose testosterone falls below normal levels are ... overweight and have heart disease and type 2 diabetes. ... men for further testing and possible treatment is described ... , a peer-reviewed publication from Mary Ann Liebert, Inc., ... Journal of Men,s Health website at http://www.liebertpub.com/jmh ...
(Date:4/23/2014)... methods that can rapidly screen a large cell ... inside that population has been seriously lacking," said ... the Royal Society of Chemistry journal Chemical ... his coworkers have developed a novel technique that ... Chem. Sci. , 2014, DOI: 10.1039/C4SC00578C, http://pubs.rsc.org/en/content/articlelanding/2014/sc/c4sc00578c#!divAbstract ...
Breaking Medicine News(10 mins):Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 3Health News:Gold nanoparticles help target, quantify breast cancer segments in a living cell 2Health News:Novel compound halts cocaine addiction and relapse behaviors 2Health News:Following a protein's travel inside cells is key to improving patient monitoring, drug development 2
... ACM Technology To Make Medical Pharmacy Claims Processing ... announced today the signing of,a new three-year contract ... it,easier for providers to submit claims for complex ... health plan. ACM,s proprietary,e-Precision claims(SM) technology will streamline ...
... 15 Althea Technologies, Inc., a leading,provider ... and manufacturing, announced today that E.J. Brandreth ... Quality and Regulatory. In this,role, Mr. Brandreth ... and,compliance programs, while overseeing the regulatory support ...
... recently held its 2008 Live Group Buy for Magnetic Resonance Imaging ... Hitachi Medical Systems America Inc. , ... Dallas, TX ... Group Buy for Magnetic Resonance Imaging (MRI), and Broadlane’s clients awarded ...
... Financial District Office Workers, Celebrities, Sports Personalities, and Corporate CEO's, are ... , ... San Francisco (PRWEB) July 15, 2008 -- ... United States has chosen Peacock Construction to bring his ...
... E-Prescribing Solution Can Help Organizations Achieve Benefits of H.R. 6331 ... ... Netsmart Technologies, Inc., a leading provider of enterprise-wide software and services ... special Web seminar to help behavioral health organizations understand e-prescribing ...
... ANGELES (STRICTLY EMBARGOED UNTIL JULY 15, 2008 AT 12:01 A.M. ... cell vaccine designed to fight malignant brain tumors called glioblastoma ... a patient,s immune response and clinical outcome, according to an ... Cancer Research . , While other studies have suggested a ...
Cached Medicine News:Health News:Blue Shield of California and ACM Sign New 3-Year Agreement 2Health News:Althea Technologies Appoints E.J. Brandreth to Vice President of Quality and Regulatory 2Health News:Broadlane's Live Group Buy Awards High-Field Open MRI Contract to Hitachi Medical Systems America Inc. 2Health News:Broadlane's Live Group Buy Awards High-Field Open MRI Contract to Hitachi Medical Systems America Inc. 3Health News:Broadlane's Live Group Buy Awards High-Field Open MRI Contract to Hitachi Medical Systems America Inc. 4Health News:Construction Begins on Executive Express Chiropractic at the SF Embarcadero Center 2Health News:Netsmart Technologies Web Seminar Helps Behavioral Health Organizations Understand Electronic Prescribing And The Importance Of New Medicare-Related E-Prescribing Legislation 2Health News:Netsmart Technologies Web Seminar Helps Behavioral Health Organizations Understand Electronic Prescribing And The Importance Of New Medicare-Related E-Prescribing Legislation 3Health News:Brain cancer study: Magnitude of post-vaccine immune response linked to clinical outcomes 2Health News:Brain cancer study: Magnitude of post-vaccine immune response linked to clinical outcomes 3
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: Global Markets ... -- Focus on End Users ... A drug delivery system is ...
(Date:1/15/2014)... Mass. , Jan. 15, 2014  Zafgen, Inc., ... unmet needs of severely obese patients, today announced ... beloranib, a selective inhibitor of methionine aminopeptidase 2 ... severe form of genetic obesity.  These results showed ...
(Date:1/14/2014)... , Jan. 14, 2014 HeartWare International, Inc ... of less invasive, miniaturized circulatory support technologies that are ... that it expects revenues for the fourth quarter of ... 2013 revenues to approximately $208 million. "Our ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
Part of the Octopus System which includes both the Starfish & Octopus3. The Starfish Heart Positioner simplifies cardiac positioning and minimizes the associated hemodynamic deterioration when compa...
... way to lift the heart - Guidant's ... 3. The XPOSE 3 is designed to ... surgery and to easily position and access ... both apical and non-apical placement on the ...
... Since its U.S. approval in 1992, ABIOMED's ... widely used advanced cardiac assist system in the ... only device approved by the U.S. Food and ... heart failure. ABIOMED continues to make advances ...
... The Arrow LionHeart Left Ventricular Assist ... is designed to be used as a ... end-stage (Class IV) congestive heart failure, for ... The Arrow LionHeart LVAS is not intended ...
Medicine Products: